Sublingual Dissolving Microneedle (SLDMN)‐Based Vaccine for Inducing Mucosal Immunity against SARS‐CoV‐2 (Adv. Healthcare Mater. 26/2023)

Theranostics In article 2300889 by Hyungil Jung and co-workers, a sublingually administered mucosal microneedle-based vaccine induces mucosal immunity against SARS-CoV-2 infection. Mucosal immunity protects a patient's lung and respiratory tract from virus infiltration by SARS-CoV-2 specific IgA and it relieves a risk of SARS-CoV-2 related cytokine release syndrome. This research suggests microneedle vaccines are a potential future mucosal vaccination system to prepare for the next pandemic.